Skip to main content
OpenTrials
Completed

NCT Number: NCT02646644

Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalaninepositron emission tomography (18F-DOPA-PET) scan.

This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan retrospectively.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuroendocrine Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Medical Center Groningen

Groningen, 9713 GZ, Netherlands

About this study

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA-PET) scan.

This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan in retrospect.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age ≥18 years
  • diagnosis of intestinal NET diagnosed by a dedicated NET specialist
  • more than one positive lesion on the 18F-DOPA-PET scan.
  • available CT-scan within 6 months before or after the 18F-DOPA-PET-scan.

Exclusion criteria

  • no clinical data available at the UMCG, besides the results of the DOPA PET scan.

Treatment and study plan

Metastasized intestinal NET

Other

This is an observational study

Primary outcomes

  1. tracer uptake in tumor lesions within patients with intestinal NET

    Time frame: at the day of scan

    The difference in tracer uptake of tumor lesions within patients with intestinal NET measured on a 18F- DOPA-PET scan.

Secondary outcomes

  1. tracer uptake in tumor lesions within patients with intestinal NET adjusted for uptake of background organ

    Time frame: at the day of scan

    The difference in tracer uptake of tumor lesions adjusted for uptake of background organ within patients with intestinal NET measured on a 18F- DOPA-PET scan.

Other outcomes

  1. the correlation of the magnitude of heterogeneity with ki 67

    Time frame: date of diagnosis until date of scan

    the correlation of the magnitude of heterogeneity between tumor lesions within patients with Intestinal NET, with the ki67 index of the tumor

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Registry information

Acronym: HET-NET

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jan 6, 2016
Registry last updated
May 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.